Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

OFT, VBP: QED?

Karl Claxton1

  • 1Department of Economics and Related Studies and Centre for Health Economics, University of York, York, UK. kpcl@york.ac.uk

Health Economics
|May 31, 2007
PubMed
Summary
This summary is machine-generated.

The UK

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health costs of the UK-US trade deal on pharmaceuticals.

BMJ (Clinical research ed.)·2026
Same author

Insights from Financial Economics to Value Healthcare Investments that Reduce System-Level Risks: Example of Disease Elimination and Eradication.

Applied health economics and health policy·2026
Same author

Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Equitable access to costly new drugs.

BMJ (Clinical research ed.)·2025
Same author

Is Caring Productive? The Effect of Adult Social Care on Paid Production in England.

Health economics·2025
Same author

Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making.

Applied health economics and health policy·2025
Same journal

Lead in Drinking Water and Child Health: Evidence From Jackson, Mississippi.

Health economics·2026
Same journal

Health on the Move: The Impact of Poverty Alleviation Relocation on Healthcare Utilization in China.

Health economics·2026
Same journal

The Effects of Compulsory Licensing: A Case Study of HIV Drugs.

Health economics·2026
Same journal

Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults' Body Weight.

Health economics·2026
Same journal

Assessing the Estimands and Estimates of Hospitalization Rates in Health Economics and Clinical Medicine.

Health economics·2026
Same journal

The Impact of Unemployment Insurance Benefit Cuts on Mental Health: Evidence From Early Pandemic Program Expirations.

Health economics·2026
See all related articles

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Health Technology Assessment

Background:

  • The UK's Pharmaceutical Price Regulation Scheme (PPRS) currently uses profit and price controls.
  • The Office of Fair Trading (OFT) has proposed reforms to the PPRS.
  • Concerns exist regarding the potential impact of these proposed reforms.

Purpose of the Study:

  • To analyze the OFT's recommendations for reforming the UK's PPRS.
  • To evaluate the potential benefits and risks of shifting to value-based pricing for pharmaceuticals.
  • To assess the implications for efficiency, innovation, and evidence-based practice within the National Health Service (NHS).

Main Methods:

  • Analysis of the OFT report and its recommendations.
  • Economic evaluation of proposed value-based pricing mechanisms.

Related Experiment Videos

  • Consideration of potential impacts on allocative and dynamic efficiency in the NHS.
  • Assessment of risks related to cost-effectiveness thresholds, pricing structures, and evidence valuation.

    • Main Results:

    • Some commonly expressed concerns about the proposed reforms may not be well-founded.
    • Value-based pricing has the potential to improve allocative and dynamic efficiency in the NHS.
    • Inappropriate implementation, such as flawed cost-effectiveness thresholds or pricing structures, poses significant risks.
    • Failure to account for uncertainty and evidence value could undermine future NHS practice.

    Conclusions:

    • The OFT's proposed shift to value-based pharmaceutical pricing could enhance NHS efficiency and innovation.
    • Careful implementation is critical to mitigate risks of negative health outcomes and damage to the evidence base.
    • The OFT report is poised to significantly influence future policy discussions on pharmaceutical value, pricing, and innovation in the UK.